Exeter Pharmaceuticals Competitors

GENESIS Pharma is a European biopharmaceutical company specializing in the commercialization of innovative pharmaceutical products for serious and rare diseases. Established in 1997, GENESIS Pharma was the first pharmaceutical company in Greece and one of the first in Europe to focus on the sales, marketing and distribution of biopharmaceutical products. Shortly after its founding, the company began to steadily expand at a regional level, currently covering 24 countries in Europe. The robust network of its strategic partnerships comprises leading international pharmaceutical companies dedicated to cutting-edge R&D, alongside fast-growing biopharmaceutical companies with pioneering research and disruptive innovations in the development of targeted, specialized treatments for orphan diseases. In total, GENESIS Pharma holds a product portfolio covering over 30 serious and rare diseases.

BioGenix grew out of the recognition of the important potential of regenerative medicine in giving hope to patients who suffer from past injuries, chronic conditions, or degenerative disease. Out of this potential grew the demand for safe, reliable, ethically sound regenerative products -- and BioGenix was up to the task. Working directly with hospitals participating in umbilical cord tissue donation programs and partnering with a trusted, sterile FDA registered lab, we turned concept into reality, bringing BioGenix regenerative products to physicians across many medical specialties domestically and around the world. By choosing to use only umbilical cord derived regenerative medicine products, we harness the medical advantages of growth-factor rich tissue while circumventing invasive procedures and providing a product that aligns with our ethics.

Fortitude Biomedicines is a private biotechnology company headquartered in Waltham, Massachusetts, pioneering next-generation immune cell targeting biologics and an antibody–drug conjugate (ADC) platform powered by proprietary molecular glue payloads. By integrating the precision targeting of ADCs with the catalytic power of targeted protein degradation, the company is developing transformative therapies with the potential to expand the therapeutic window of ADCs, overcome resistance mechanisms, and unlock new target space. Leveraging a robust discovery engine and an experienced team of drug hunters, Fortitude is building a differentiated pipeline of biologics and ADCs aimed at delivering meaningful benefits to patients with high unmet medical need. Investor Relations and Media Contact IR@fortitudebio.com